Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 12, 2026

I’m 66, have a paid-off house and $100K sitting in cash. Would this be a good time to invest it all in the S&P 500?

View original at finance.yahoo.com
“She also has about $100,000 in cash sitting in a high-yield savings account”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The stock market isn't pricing current events but rather what the world will look like six to 12 months from now

    60% confidence
  • There are concerns that the S&P 500 stock market rally cannot last forever

    60% confidence
  • Investors are betting the Iran conflict will be short-lived and that China can push Tehran toward de-escalation following the Trump-Xi meeting

    60% confidence
  • The S&P 500 is 16.5% above this year's low

    60% confidence
  • A specific unidentified asset will surge 400% in a year; investors should not miss this 'explosion'

    60% confidence
  • The blockade of the Strait of Hormuz has led to the largest oil-supply disruption in history

    60% confidence
  • Nearly 50% of Americans are making one big Social Security mistake that should be fixed immediately

    60% confidence
  • S&P 500 gains have been driven in part by high demand for new data centers to fuel the rapid growth of AI, despite inflation concerns from rising oil prices

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com